Exelixis, Inc. (NASDAQ:EXEL) – Equities researchers at William Blair issued their Q1 2018 earnings per share (EPS) estimates for Exelixis in a research report issued to clients and investors on Wednesday. William Blair analyst A. Hsieh forecasts that the biotechnology company will post earnings per share of $0.09 for the quarter. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Exelixis’ Q2 2018 earnings at $0.10 EPS, Q3 2018 earnings at $0.15 EPS, Q4 2018 earnings at $0.20 EPS and FY2018 earnings at $0.55 EPS.

Other research analysts have also recently issued research reports about the stock. TheStreet upgraded shares of Exelixis from a “c” rating to a “b-” rating in a research report on Monday. Piper Jaffray Companies restated a “buy” rating and issued a $29.00 price objective on shares of Exelixis in a research report on Thursday, August 3rd. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Exelixis in a research report on Monday, June 5th. Stifel Nicolaus restated a “hold” rating and issued a $26.00 price objective on shares of Exelixis in a research report on Thursday, August 3rd. Finally, Deutsche Bank AG cut shares of Exelixis from a “buy” rating to a “hold” rating and boosted their price objective for the stock from $26.00 to $29.00 in a research report on Thursday, August 3rd. Five investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $25.57.

COPYRIGHT VIOLATION NOTICE: “Exelixis, Inc. (NASDAQ:EXEL) Expected to Earn Q1 2018 Earnings of $0.09 Per Share” was reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.dailypolitical.com/2017/08/09/exelixis-inc-nasdaqexel-expected-to-earn-q1-2018-earnings-of-0-09-per-share.html.

Exelixis (NASDAQ:EXEL) traded up 1.18% during mid-day trading on Monday, reaching $27.52. The company had a trading volume of 1,422,281 shares. Exelixis has a 52-week low of $10.04 and a 52-week high of $28.45. The stock has a market capitalization of $8.09 billion, a price-to-earnings ratio of 143.33 and a beta of 1.89. The company’s 50 day moving average is $25.47 and its 200 day moving average is $21.97.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. Exelixis had a return on equity of 80.43% and a net margin of 18.20%. The firm had revenue of $99.01 million for the quarter, compared to analysts’ expectations of $85.27 million. During the same period last year, the firm earned ($0.15) EPS. The firm’s revenue was up 173.1% compared to the same quarter last year.

In other Exelixis news, Director Carl B. Feldbaum sold 32,988 shares of the company’s stock in a transaction on Monday, May 15th. The shares were sold at an average price of $21.58, for a total transaction of $711,881.04. Following the completion of the sale, the director now owns 52,721 shares in the company, valued at approximately $1,137,719.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Patrick J. Haley sold 5,000 shares of the company’s stock in a transaction on Tuesday, May 30th. The shares were sold at an average price of $18.46, for a total transaction of $92,300.00. The disclosure for this sale can be found here. Insiders own 5.10% of the company’s stock.

Several hedge funds have recently modified their holdings of EXEL. BlackRock Inc. boosted its stake in shares of Exelixis by 33,678.5% in the first quarter. BlackRock Inc. now owns 19,155,466 shares of the biotechnology company’s stock valued at $415,099,000 after buying an additional 19,098,757 shares during the last quarter. Old Mutual Global Investors UK Ltd. boosted its stake in shares of Exelixis by 237.5% in the first quarter. Old Mutual Global Investors UK Ltd. now owns 5,041,260 shares of the biotechnology company’s stock valued at $109,244,000 after buying an additional 3,547,665 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Exelixis by 12.8% in the first quarter. Vanguard Group Inc. now owns 23,735,071 shares of the biotechnology company’s stock valued at $514,339,000 after buying an additional 2,696,877 shares during the last quarter. Meditor Group Ltd boosted its stake in shares of Exelixis by 5.5% in the second quarter. Meditor Group Ltd now owns 20,229,713 shares of the biotechnology company’s stock valued at $498,258,000 after buying an additional 1,046,000 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its stake in shares of Exelixis by 167.1% in the first quarter. Wells Fargo & Company MN now owns 1,460,194 shares of the biotechnology company’s stock valued at $31,642,000 after buying an additional 913,454 shares during the last quarter. Institutional investors own 80.19% of the company’s stock.

About Exelixis

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Earnings History and Estimates for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.